Fosravuconazole

Fosravuconazole (trade name Nailin) is a triazole antifungal agent.^[1][2] In Japan, it is approved for the treatment of onychomycosis, a fungal infection of the nail.^[3] It is a prodrug that is converted into ravuconazole.^[1]

Trade namesNailin

Other namesBMS-379224; BFE-1224; E-1224

ATC code

• D01BA03 (WHO)

Legal status

• In general: ℞ (Prescription only)

Quick facts Clinical data, Trade names ...

Fosravuconazole

Clinical data
Trade names	Nailin
Other names	BMS-379224; BFE-1224; E-1224
ATC code	D01BA03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Identifiers
IUPAC name [(2R,3R)-3-[4-(4-Cyanophenyl)-1,3-thiazol-2-yl]-2-(2,4-difluorophenyl)-1-(1,2,4-triazol-1-yl)butan-2-yl]oxymethyl dihydrogen phosphate
CAS Number	351227-64-0
PubChem CID	9807507
DrugBank	DB15204
ChemSpider	7983266
UNII	L4Q6O5430L
KEGG	D10762
ChEBI	CHEBI:34549
ChEMBL	ChEMBL333325
CompTox Dashboard (EPA)	DTXSID70188627
Chemical and physical data
Formula	C23H20F2N5O5PS
Molar mass	547.47 g·mol−1
3D model (JSmol)	Interactive image
SMILES C[C@@H](c1nc(-c2ccc(C#N)cc2)cs1)[C@@](Cn1cncn1)(OCOP(=O)(O)O)c1ccc(F)cc1F
InChI InChI=1S/C23H20F2N5O5PS/c1-15(22-29-21(10-37-22)17-4-2-16(9-26)3-5-17)23(11-30-13-27-12-28-30,34-14-35-36(31,32)33)19-7-6-18(24)8-20(19)25/h2-8,10,12-13,15H,11,14H2,1H3,(H2,31,32,33)/t15-,23+/m0/s1 Key:SYTNEMZCCLUTNX-NPMXOYFQSA-N

Close

Drugs for Neglected Diseases Initiative (DNDi) and the Japanese pharmaceutical company Eisai found that fosravuconazole works as a treatment for mycetoma, a serious condition.^[1][4][5] The Phase II clinical trial found that oral fosravuconazole was safe, patient-friendly, and effective in treating eumycetoma.^[6][7] Eumycetoma mainly affects young adults in poorer, rural areas; the standard treatment is itraconazole, which is much more expensive at about US$2,000 for a year than fosravuconazole and unaffordable, and not available in all endemic countries.^[7]